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OBJECTIVES: To establish a conceptual framework to estimate the resources needed 
to start a population-based cancer screening program and to estimate its long-term 
impact in terms of beneﬁt and resource use. METHODS: A conceptual model was 
deﬁned according to discrete-event simulation methodology. The conceptual model 
included, on one hand, the stages of a screening program and, on the other hand, the 
natural history of the disease. The stages of a screening program included: invitation 
of the target population, participation and screening test, conﬁrmation test(s) after a 
positive screening result, cancer diagnosis and cancer treatment. The natural history 
of the disease includes the following states: free of cancer, pre-clinical cancer phase, 
clinical (or symptomatic) cancer phase and cancer cured, including recurrences and 
death. The natural history of the disease will be modeled as time until a change of 
state, and this health states will be managed as attributes. Then, the health state will 
be taken into account through the process of screening to choose which sensitivities 
and speciﬁcities of the screening and conﬁrmatory tests should be applied. It will also 
be used to detect interval cancers. CONCLUSIONS: Using a simulation model to 
reproduce a population-based cancer screening program will allow estimating the 
amount of resources needed to implement the program. This will be applicable to 
cancers for which screening is recommended, such as colorectal cancer, but also to 
explore changes in the screening strategy such as widening of the age range for breast 
cancer screening.
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The market access of innovative technology is perceptibly tensing up. Beyond cost-
effectiveness, payers increasingly scrutinize budget impact (BI) and contemplate risk-
sharing (RS) agreements. In these conditions, accurate forecasting of an innovation 
uptake and diffusion (IUD) is decisive as it determines the new technology mix evolu-
tion over time. The IUD rate is a key feature of BI modelling and cannot strategically 
be ignored in potential RS proposals in which the number of patients being given the 
innovation over time may determine RS agreement conditions. However, in the BI 
analysis and RS experiences carried out so far, it is not necessarily clear how IUD 
rates were factored in. This contribution builds upon methods developed in the tech-
nological forecasting science to predict new technology diffusion with little or no data. 
We describe the use of sigmoid growth curves (Logistic or Gompertz functions for 
instance) to account for the gradual and continuous process of an IUD within a speciﬁc 
market. Growth curves are mathematically tractable. They provide modellers and 
decision makers with remarkable ﬂexibility and transparency to run a broad range of 
adaptations, sensitivity and scenario analysis on an IUD path in BI models or RS 
proposals i.e., in simulating and comparing different market dynamics and new tech-
nology mix evolution. Bayesian updating is also described to improve curve ﬁtting in 
order to increase the accuracy of IUD forecasts as expert opinions and preliminary 
claims or sales data become available.
PMC45
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OBJECTIVES: The NICE Single Technology Appraisal process requires a systematic 
review of existing economic evaluations to be submitted. A critical appraisal of the 
identiﬁed studies is an important component of this review. Numerous quality assess-
ment tools have been devised to critically appraise the quality of decision models. 
However, none of these accurately reﬂect the quality criteria speciﬁed by the NICE 
Reference Case published in the updated 2008 Guide to the Methods of Technology 
Appraisal. We aimed to develop a checklist for assessing the quality of decision-analytic 
models that may be used in the context of STA submissions, and which reﬂects the 
requirements of the NICE reference case, and incorporates important elements of 
existing highly regarded tools. METHODS: A systematic review was undertaken to 
identify existing good practice guidelines and checklists for critical appraisal of health 
economics studies. We searched MEDLINE, EconLit and Health Economic Evaluations 
Database (HEED) for published guidelines and checklists, and the Internet for relevant 
grey literature, discussion papers and conference abstracts. RESULTS: We identiﬁed 
17 relevant publications. These were summarised and synthesised to determine the 
most important appraisal criteria. Based on these ﬁndings and the NICE 2008 Methods 
Guide, we propose a simple checklist which provides a means to assess the quality of 
models and the evidence underpinning them according to the Reference Case and 
evidence hierarchy speciﬁed by NICE, including identiﬁcation of evidence by systematic 
review, and selection and synthesis of outcomes data and measuring and valuing health 
effects. CONCLUSIONS: We believe the proposed checklist will provide a useful 
means for assessing the quality of health economics evaluations reﬂecting the most 
up-to-date Reference Case requirements. The checklist may be used alongside recog-
nized guidelines for critical appraisal of health economics evaluations.
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Cancer natural history models are essential when evaluating screening interventions, 
preventative interventions or changes to diagnostic pathways. Natural history models 
commonly use a state transition structure where the progression of disease is split 
into distinct disease states but it is often not possible to directly observe the state 
transition probabilities required to parameterise such a model. An existing Excel 
markov state transition model for the natural history of colorectal cancer (CRC) was 
modiﬁed and updated with recent English data. The work aimed to accurately repre-
sent the uncertainty in natural history parameters by embedding the problem in the 
framework of Bayesian inference. The Metropolis-Hastings algorithm was used to 
estimate natural history parameters by generating multiple sets of parameters from 
the posterior distribution, which is a probability distribution that is compatible with 
the observed data. Observed data included incidence categorised by age and stage, 
autopsy data on polyp prevalence, and cancer and polyp detection rates from the ﬁrst 
round of screening. The approach was implemented using Visual Basic within the 
EXCEL model and the results were subsequently examined for convergence using the 
package CODA in R 2.8.0. Outputs from the ﬁtting process were samples from the 
joint posterior distribution of the natural history parameters given the epidemiological 
data. These parameter sets are used when running PSA. The advantages of this strategy 
are that it draws efﬁciently (compared to simple Monte Carlo or Latin Hypercube) 
from a high dimensional correlated parameter space. The underlying methodology is 
well developed in the Bayesian literature. The algorithm is simple to code and could 
be run overnight on a standard desktop PC. Using this method the parameter sets are 
drawn according to their posterior probability given calibration data and thus they 
correctly summarise the residual uncertainty in the parameter space given the data 
that are available.
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OBJECTIVES: When the course of therapy is long—particularly if treatment is expen-
sive and/or associated with signiﬁcant side effects—standards of care often include an 
early assessment of treatment effectiveness. If this “mid-therapy” assessment is posi-
tive, the patient is indicated to continue treatment; if negative, treatment is discontin-
ued. Using expected utility theory, we demonstrated previously that the availability 
and timing of such assessments can serve as a mechanism by which policymakers can 
inﬂuence patients’ treatment initiation decisions. Here, we demonstrate the interaction 
between the timing of mid-therapy assessment, willingness to initiate (WTI) therapy, 
and treatment success using an application to hepatitis C virus (HCV) treatment. 
METHODS: A simple decision tree framework was used to compare the number of 
treatment successes for a hypothetical population of 1000 patients when initial mid-
therapy assessments are conducted at 2-weeks (wks), 4-wks, and the current standard 
of care, 12-wks, with and without considerations of WTI. Test performance charac-
teristics were based on published reports. Hypothetical treatment initiation probabili-
ties were derived from the expected burden of side effects and the prior probability 
of treatment success associated with each assessment considered. RESULTS: Ignoring 
WTI, the 12-wk strategy is associated with the most expected treatment successes (471 
vs 439 and 406 for 4- and 2-wk strategies, respectively). When WTI was inversely 
proportionate to expected side effect burden, the 2-wk strategy produced more treat-
ment successes (222 vs. 190 and 141 for 4- and 12-wk strategies, respectively). If WTI 
for the 2-wk assessment exceeded 115% of the WTI for 12-wks, the 2-wk strategy 
dominated. CONCLUSIONS: The optimal timing of a mid-therapy assessment 
depends on test performance and the relative importance of side effects and treatment 
success to patients. Understanding patients’ treatment preferences can help decision 
makers design treatment guidelines that have the greatest potential to reach public 
health goals.
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To effectively control infectious diseases, great efforts have been made using empirical 
and theoretical approaches to explore the age-related characteristics of various infec-
tious diseases, such as the force of infection (FOI), the per capita rate that a susceptible 
from a certain age is infected. Among them, mathematical epidemic models have 
contributed greatly to the control of infection within population. With the relaxed 
